Posts by Andrew

Palantir Pharma: mitigating R&D risk through data fusion

With development times of ten years or more and costs of over $1 billion per new medicine, pharmaceutical R&D is an expensive, lengthy, and risky process. Enterprises can minimize the risk associated with drug development programs by better understanding the universe of data relevant to particular diseases, targets, and drug candidates. Unfortunately, achieving this level of [...]

Continue reading »